BMRN
BioMarin Pharmaceutical Inc. · Healthcare · Biotechnology
Señales de momentum (gestores comparables):
amplitud de titulares -4.2% ·
flujo de acciones -6.6% ·
nuevas posiciones netas -8.7%
· fórmula
Distribución amplia: acciones en descenso y menos titulares
Todas las cifras de propiedad: únicamente gestores 13F seguidos, posiciones en acciones ordinarias, período de referencia Q3 2025
| Trimestre | Titulares | Δ | Acciones | Valor declarado | Nuevo | Cierres |
|---|---|---|---|---|---|---|
| Q3 2026 | 2 | 0 | 1.42M | $84.45M | n/a | −1 |
| Q2 2026 | 135 | +4 | 146.70M | $8.39B | +11 | −8 |
| Q1 2026 | 135 | -4 | 142.18M | $8.03B | +5 | −10 |
| Q4 2025 | 138 | +3 | 154.93M | $9.20B | +4 | n/a |
| Q3 2025 | 23 | -1 | 108.93M | $5.90B | n/a | −2 |
| Q2 2025 | 22 | -2 | 113.78M | $6.25B | n/a | −2 |
| Q1 2025 | 21 | 0 | 70.58M | $4.99B | +1 | −1 |
| Q4 2024 | 21 | +1 | 67.83M | $4.46B | +1 | n/a |
| Q3 2024 | 19 | 0 | 57.19M | $4.02B | +2 | −2 |
| Q2 2024 | 19 | n/a | 53.80M | $4.43B | n/a | n/a |
| # | Gestor | Acciones | Δ acciones | Valor | Su ponderación | Mantenida | ||
|---|---|---|---|---|---|---|---|---|
| 1 | BlackRock ✦ (pasivo) | 22.05M | -8.2% | $1.19B | 0.0% | ▼ Trim | 2 | SEC ↗ ×21 |
| 2 | The Vanguard Group ✦ (pasivo) | 18.58M | -2.2% | $1.01B | 0.0% | ▼ Trim | 2 | SEC ↗ ×6 |
| 3 | PRIMECAP Management ✦ | 15.23M | -3.4% | $824.82M | 0.6% | ▼ Trim | 6 | SEC ↗ |
| 4 | Dodge & Cox ✦ | 14.69M | -2.8% | $795.44M | 0.4% | ▼ Trim | 6 | SEC ↗ |
| 5 | State Street Global Advisors ✦ (pasivo) | 8.76M | -0.9% | $474.69M | 0.0% | ▼ Trim | 4 | SEC ↗ |
| 6 | Viking Global Investors ✦ | 8.32M | -32.3% | $450.73M | 1.2% | ▼ Trim | 6 | SEC ↗ |
| 7 | AQR Capital Management ✦ | 5.93M | +6.3% | $321.28M | 0.2% | ▲ Add | 6 | SEC ↗ ×7 |
| 8 | Geode Capital Management ✦ (pasivo) | 3.54M | +1.9% | $191.29M | 0.0% | ▲ Add | 6 | SEC ↗ ×2 |
| 9 | Millennium Management ✦ | 2.63M | -7.3% | $142.29M | 0.1% | ▼ Trim | 6 | SEC ↗ |
| 10 | Goldman Sachs Group ✦ | 2.29M | n/a | $124.08M | 0.0% | n/c | 1 | SEC ↗ ×4 |
| 11 | Renaissance Technologies ✦ | 1.89M | +4.8% | $102.56M | 0.1% | ▲ Add | 6 | SEC ↗ |
| 12 | Morgan Stanley ✦ | 1.38M | n/a | $74.76M | 0.0% | n/c | 1 | SEC ↗ ×14 |
| 13 | JPMorgan Chase ✦ | 1.20M | n/a | $64.89M | 0.0% | n/c | 1 | SEC ↗ ×18 |
| 14 | Citadel Advisors ✦ | 397.85K | +18.8% | $21.55M | 0.0% | ▲ Add | 6 | SEC ↗ ×2 |
| 15 | Fidelity (FMR) ✦ | 392.81K | -28.1% | $21.27M | 0.0% | ▼ Trim | 2 | SEC ↗ ×5 |
| 16 | Bridgewater Associates ✦ | 375.68K | +65.0% | $20.35M | 0.1% | ▲ Add | 6 | SEC ↗ |
| 17 | Arrowstreet Capital ✦ | 374.71K | +34.5% | $20.29M | 0.0% | ▲ Add | 3 | SEC ↗ |
| 18 | D. E. Shaw & Co. ✦ | 275.24K | -75.3% | $14.91M | 0.0% | ▼ Trim | 6 | SEC ↗ |
| 19 | Gotham Asset Management ✦ | 265.33K | +122.1% | $14.37M | 0.1% | ▲ Add | 5 | SEC ↗ |
| 20 | Two Sigma Investments ✦ | 157.59K | +6.8% | $8.53M | 0.0% | ▲ Add | 6 | SEC ↗ |
| 21 | T. Rowe Price ✦ | 148.03K | +7.3% | $8.02M | 0.0% | ▲ Add | 6 | SEC ↗ ×2 |
| 22 | Fisher Asset Management ✦ | 31.73K | +134.2% | $1.72M | 0.0% | ▲ Add | 6 | SEC ↗ |
| 23 | GAMCO Investors ✦ | 13.15K | +64.4% | $712,204 | 0.0% | ▲ Add | 6 | SEC ↗ |
"Their weight" = la participación de la posición en el valor de renta variable 13F reportado por ese manager: la medida de convicción. ✦ = manager curado.
Nuevos compradores
| Sin nuevos compradores rastreados este trimestre. |
Posición cerrada
| Norges Bank | $112.35M | era 0.0% |
| Marshall Wace | $4.61M | era 0.0% |
Contexto de mercado completo: entre TODOS los filers 13F (datos estructurados SEC, Q1 2026): 549 tenedores, 183.01M acciones, $10.09B declarado. Este es un período diferente y anterior al de las cifras del universo rastreado que figuran arriba, y ambos nunca se mezclan.
Qué más suelen tener los titulares rastreados de este valor: recuentos de titularidad compartida, no relaciones fundamentales.
Compras en mercado abierto (P)
Sin compras en mercado abierto por parte de insiders en nuestra ventana de cobertura.
Ventas en mercado abierto (S)
Officer · 17.56K acc. · $1.16M
Las adjudicaciones, ejercicios y retenciones fiscales nunca se contabilizan aquí como compras o ventas. Metodología